



Proteomics International

LABORATORIES LTD

ASX Release

16 December 2021

ASX code: PIQ

Proteomics International secures major contract amid strong demand for pharmacokinetic testing services

- **Proteomics International awarded \$409,000 pharmacokinetic testing contract with Linear Clinical Research**
- **Study will test a novel drug for degenerative and inflammatory diseases on behalf of pharmaceutical company Sironax Ltd**
- **Contract comes amid strong global demand for pharmacokinetic testing and other analytical services**
- **Agreement supports Proteomics International's integrated business model and wider strategic vision to exploit its specialised biomarker discovery and analytical services capabilities**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has been awarded a major pharmacokinetic testing contract as part of its growing partnership with Linear Clinical Research.

The \$409,000 contract will see Proteomics International test a novel drug for degenerative and inflammatory diseases on behalf of the Australian arm of pharmaceutical company Sironax Ltd. The study is part of a Phase I clinical trial examining the safety, tolerability and pharmacokinetics of the drug, and will be undertaken over the next 12 months. Pharmacokinetics is the study of what happens to drugs once they are inside the body, including the rate at which they are absorbed, distributed, metabolised and excreted.

Proteomics International managing director Dr Richard Lipscombe said the contract with Linear was one of Proteomics International's largest to date. *"With Australia as a leading destination for clinical trials, we are seeing strong demand for our specialist testing services in this fast-growing space,"* he said.

Proteomics International's pharmacokinetic testing capabilities operate under a suite of global laboratory accreditations, which recognise the Company's ability to consistently achieve technically valid, traceable and reproducible results. These include ISO 17025 Chemical Testing, ISO 17025 R&D with Good Laboratory Practice overlay, and the discrete ISO 13485 for Medical Devices.

Proteomics International's portfolio of analytical services also encompasses proteomics, biosimilars, and biomarker discovery and validation. *"Proteomics International's strengthened pharmacokinetic testing business continues to boost our analytical services revenue, which in turn helps offset the expenditure on our pioneering diagnostics pipeline, and its development and commercialisation,"* Dr Lipscombe said.

"This area of contract research is a hot area globally, and is seeing lots of investment alongside mergers and acquisitions. It's exciting to see this as we pursue our strategic vision to exploit our unique capabilities across analytical services and specialised biomarker discovery."

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Authorised by the Board of Proteomics International Laboratories Ltd (ASX:PIQ).

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Kyle Moss
Corporate Advisor
Euroz Hartleys
T: +61 8 9488 1400
E: kmoss@eurozhartleys.com